The potential of phage therapy in bacterial infections of the eye

Ophthalmologica

Volumn 223, Issue 3, 2009, Pages 162-165

  Górski, Andrzej ^a,c   Targońska, Magdalena ^b   Borysowski, Jan ^c   Weber Da̧browska, Beata ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b REGIONAL SPECIALIST HOSPITAL   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Antibiotic resistance; Eye infections; Methicillin resistant Staphylococcus aureus; Phage

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CIPROFLOXACIN; ERYTHROMYCIN; EYE DROPS; VANCOMYCIN;

ABSCESS; ABSENCE OF SIDE EFFECTS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL EYE INFECTION; BACTERIOPHAGE; BLEPHARITIS; BLINDNESS; CLINICAL TRIAL; CONJUNCTIVITIS; DISEASE PREDISPOSITION; DRUG EFFICACY; ENDOPHTHALMITIS; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; OPHTHALMOLOGY; ORBIT CELLULITIS; PANOPHTHALMITIS; SHORT SURVEY;

ANIMALS; BACTERIOPHAGES; BIOLOGICAL THERAPY; DRUG RESISTANCE, BACTERIAL; EYE INFECTIONS, BACTERIAL; HUMANS;

EID: 58249145217     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000193293     Document Type: Short Survey

References (24)

1. Selgelid MJ: Ethics and drug resistance. Bioethics 2007;21:218-229.
2. Hausler T: Bugkillers. Nat Med 2006;12:600-601.
3. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumvati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK: Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298:1763-1771.
4. Freidlin J, Acharya N, Lietman TM, Cevallos V, Whitcher JP, Margolis TP: Spectrum of eye disease caused by methicillin-resistant Staphylococcus aureus. A m J Opthalmol 2007; 144:313-315.
5. Blomquist PH: Methicillin-resistant Staphylococcus aureus infections of the eye and orbit. Trans Am Ophthalmol Soc 2006;104:322-345.
6. Kubal A, Garibaldi DC: Dacryoadenitis caused by methicillin-resistant Staphylococcus aureus. Ophtha l Plast Reconstr Surg 2008; 24:50-51.
7. Khosravi AD, Mehdinejad M, Heidari M: Bacteriological findings in patients with ocular infections and antibiotic susceptibility patterns of isolated pathogens. Singapore Med J 2007;48:741-743.
8. Gregory M, Gilmore MS, Callegan MC: Role of bacterial and host factors in infectious endophthalmitis; in Niederkorn JY, Kaplan HJ (eds): Immune Response and the Eye. Chem Immunol Allergy, Basel, Karger, 2007, vol. 92, pp 1-10.
9. Burgess EH, Mora Vieira LF: Endogenous endophthalmitis. N Engl J Med 2007;357: 163.
10. Deramo VA, Lai JC, Winokur J, Luchs J, Udell IJ: Visual outcome and bacterial sensitivity after methicillin-resistant Staphylococcus aureus -associated acute endophthalmitis. Am J Ophthalmol 2008;145:413-417.
11. Capparelli R, Parlato M, Borriello G, Salvatore P, Iannelli D: Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother 2007;51: 2765-2773.
12. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B, Carlton R, Merril CA: Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 2002;70:204-210.
13. Wang J, Hu B, Xu M, Yan O, Liu S, Zhu X, Sun Z, Reed E, Ding L, Gong J, Li QQ, Hu J: Use of bacteriophage in the treatment of experimental bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int J Mol Med 2006;17:309-317.
14. Wang J, Hu B, Xu M, Yan O, Liu S, Zhu X, Sun Z, Tao D, Ding L, Reed E, Gong J, Li QQ, Hu J: Therapeutic effectiveness of bacteriophages in the rescue of mice with extended-spectrum beta-lactamase-producing Escherichia coli bacteremia. Int J Mol Med 2006;17:347-355.
15. Górski A, Borysowski J, Miȩdzybrodzki J, Weber-Da̧browska B: Bacteriophages in medicine; in McGrath S, van Sinderen D (eds): Bacteriophage: Genetics and Molecular Biology. Norfolk, Caister Academic Press, 2007, pp 125-158.
16. Kropinski AM: Phage therapy - everything old is new again. Can J Infect Dis Med Microbiol 2006;17:297-306.
17. Marza JA, Soothill JS, Boydell P, Collyns TA: Multiplication of therapeutically administered bacteriophages in Pseudomonas aeruginosa infected patients. Burns 2006;32: 644-646.
18. Borysowski J, Górski A: Is phage therapy acceptable in the immunocompromised host? Int J Infect Dis 2008;12:466-471.
19. Proskurov WA: Treatment of staphylococcal eye infections. Vestn Ophthalmol 1970;6: 82-83.
20. Ślopek S, Weber-Da̧browska B, Da̧browski M, Kucharewicz-Krukowska A: Results of treatment of suppurative bacterial infections in the years 1981-1986. Arch Immunol Ther Exp (Warsz) 1987;35:569-583.
21. Hollyfield JG, Boniha VL, Rayborn ME, Yang X, Shadrach KG, Lu L, Ufret RL, Salomon RG: Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat Med 2008;14:194-198.
22. Miȩdzybrodzki R, Fortuna W, Weber-Da̧browska B, Górski A: Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment. Postepy Hig Med Dosw (Online) 2007;61: 461-465.
23. Barequet IS, Ben Simon GJ, Safrin M, Ohman DE, Kessler E: Pseudomonas aeruginosa LasA protease in treatment of experimental staphylococcal keratitis. Antimicrob Agents Chemother 2004;48:1681-1687.
24. Rubinstein E, Zhanel GG: Anti-infective research and development - problems, challenges, and solutions. Lancet Infect Dis 2007; 7:68-78.